News coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a news impact score of 0.06 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.7612625324152 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Harry Boxer’s six stocks to watch, including two short-sale candidates (finance.yahoo.com)
- ImmunoGen, Inc., (NASDAQ: IMGN) – Volatility Factor to Consider – Stock Watch (stocksnewstimes.com)
- Immunogen Inc (IMGN) Trend Analysis Report – Emn News (emnnews.com)
- Investors Recap on ImmunoGen, Inc. (IMGN) with Unusual Volume – Wall Street Morning (wallstreetmorning.com)
- Commit To Buy ImmunoGen At $8, Earn 31.6% Annualized Using Options – Nasdaq (nasdaq.com)
A number of brokerages have weighed in on IMGN. HC Wainwright started coverage on ImmunoGen in a research report on Wednesday, January 31st. They issued a “buy” rating for the company. BidaskClub upgraded ImmunoGen from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 9th. ValuEngine downgraded ImmunoGen from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Zacks Investment Research downgraded ImmunoGen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 14th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $12.00 price target on shares of ImmunoGen in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.21.
ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03). The firm had revenue of $39.40 million during the quarter, compared to analysts’ expectations of $39.62 million. ImmunoGen’s revenue was up 185.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.39) earnings per share. research analysts anticipate that ImmunoGen will post -1.09 EPS for the current year.
In other news, CEO Mark J. Enyedy sold 67,717 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $10.87, for a total transaction of $736,083.79. Following the completion of the transaction, the chief executive officer now directly owns 532,383 shares of the company’s stock, valued at approximately $5,787,003.21. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel M. Junius sold 25,000 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $11.68, for a total value of $292,000.00. Following the transaction, the director now directly owns 196,700 shares of the company’s stock, valued at $2,297,456. The disclosure for this sale can be found here. Insiders sold 197,834 shares of company stock worth $2,118,633 in the last 90 days. Company insiders own 6.51% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ImmunoGen (IMGN) Getting Somewhat Favorable Media Coverage, Report Shows” was first posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-immunogen-imgn-stock-price/1971598.html.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.